Literature DB >> 21962305

Hypoxia-reduced nitric oxide synthase activity is partially explained by higher arginase-2 activity and cellular redistribution in human umbilical vein endothelium.

C P Prieto1, B J Krause, C Quezada, R San Martin, L Sobrevia, P Casanello.   

Abstract

Hypoxia relates with altered placental vasodilation, and in isolated endothelial cells, it reduces activity of the endothelial nitric oxide synthase (eNOS) and l-arginine transport. It has been reported that arginase-2 expression, an alternative pathway for l-arginine metabolism, is increased in adult endothelial cells exposed to hypoxia as well as in pre-eclamptic placentae. We studied in human umbilical vein endothelial cells (HUVEC) whether hypoxia-reduced NO synthesis results from increased arginase-mediated l-arginine metabolism and changes in subcellular localization of eNOS and arginase-2. In HUVEC exposed (24 h) to 5% (normoxia) or 2% (hypoxia) oxygen, l-arginine transport kinetics, arginase activity (urea assay), and NO synthase (NOS) activity (l-citrulline assay) were determined. Arginase-1, arginase-2 and eNOS expression were determined by RT-PCR and Western blot. Subcellular localization of arginase-2 and eNOS were studied using confocal microscopy and indirect immunofluorescence. Experiments were done in absence or presence of S-(2-boronoethyl)-l-cysteine-HCl (BEC, arginase inhibitor) or N(G)-nitro-l-arginine methyl ester (l-NAME). Hypoxia-induced reduction in eNOS activity was associated with a reduction in eNOS phosphorylation at Serine-1177 and increased phosphorylation at Threonine-495. This was paralleled with an induction in arginase-2 expression and activity, and decreased l-arginine transport. In hypoxia the arginase inhibition, restored NO synthesis and l-arginine transport, without changes in the eNOS post-translational modification status. Hypoxia increased arginase-2/eNOS colocalization, and eNOS redistribution to the cell periphery. Altogether these data reinforce the thought that eNOS cell location, post-translational modification and substrate availability are important mechanisms regulating eNOS activity. If these mechanisms occur in pregnancy diseases where feto-placental oxygen levels are reduced remains to be clarified.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21962305     DOI: 10.1016/j.placenta.2011.09.003

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  16 in total

1.  Serum Arginase II level can be a novel indicator for erectile dysfunction in patients with vasculogenic erectile dysfunction: a comparative study.

Authors:  Abdel Shakour Abdel Hafez Abdel Wahed; Mohamed Abdel Mawgood Amer; Nagah Mohamed Abou Mohamed; Mohamed Ismael Mobasher; Hassan Mamdouh; Sameh Fayek GamalEl Din; Mohammed Said ElSheemy
Journal:  Int Urol Nephrol       Date:  2018-06-28       Impact factor: 2.370

2.  Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability.

Authors:  Gustavo H Oliveira-Paula; Fernanda Borchers Coeli-Lacchini; Letícia Perticarrara Ferezin; Graziele C Ferreira; Lucas C Pinheiro; Waynice N Paula-Garcia; Luis V Garcia; Jose E Tanus-Santos; Riccardo Lacchini
Journal:  Eur J Clin Pharmacol       Date:  2021-01-07       Impact factor: 2.953

3.  Arginase inhibition enhances angiogenesis in endothelial cells exposed to hypoxia.

Authors:  Lin Wang; Anil Bhatta; Haroldo A Toque; Modesto Rojas; Lin Yao; Zhimin Xu; Chintan Patel; Ruth B Caldwell; R William Caldwell
Journal:  Microvasc Res       Date:  2014-11-07       Impact factor: 3.514

4.  Influence of arginase polymorphisms and arginase levels/activity on the response to erectile dysfunction therapy with sildenafil.

Authors:  R Lacchini; J J Muniz; Y T D A Nobre; A J Cologna; A C P Martins; J E Tanus-Santos
Journal:  Pharmacogenomics J       Date:  2017-04-04       Impact factor: 3.550

Review 5.  The Arginase Pathway in Neonatal Brain Hypoxia-Ischemia.

Authors:  Jana Krystofova; Praneeti Pathipati; Jeffrey Russ; Ann Sheldon; Donna Ferriero
Journal:  Dev Neurosci       Date:  2019-04-17       Impact factor: 2.984

6.  Regulation of cardiac nitric oxide signaling by nuclear β-adrenergic and endothelin receptors.

Authors:  George Vaniotis; Irina Glazkova; Clémence Merlen; Carter Smith; Louis R Villeneuve; David Chatenet; Michel Therien; Alain Fournier; Artavazd Tadevosyan; Phan Trieu; Stanley Nattel; Terence E Hébert; Bruce G Allen
Journal:  J Mol Cell Cardiol       Date:  2013-05-17       Impact factor: 5.000

7.  Folic Acid Promotes Recycling of Tetrahydrobiopterin and Protects Against Hypoxia-Induced Pulmonary Hypertension by Recoupling Endothelial Nitric Oxide Synthase.

Authors:  Karel Chalupsky; Damir Kračun; Ivan Kanchev; Katharina Bertram; Agnes Görlach
Journal:  Antioxid Redox Signal       Date:  2015-11-05       Impact factor: 8.401

8.  Effectiveness of arginase inhibitors against experimentally induced stroke.

Authors:  Waleed Barakat; Ahmad Fahmy; Mohamed Askar; Sherif El-Kannishy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-29       Impact factor: 3.000

Review 9.  Arginase as a Critical Prooxidant Mediator in the Binomial Endothelial Dysfunction-Atherosclerosis.

Authors:  Luiza A Rabelo; Fernanda O Ferreira; Valéria Nunes-Souza; Lucas José Sá da Fonseca; Marília O F Goulart
Journal:  Oxid Med Cell Longev       Date:  2015-05-04       Impact factor: 6.543

Review 10.  Roles of nitric oxide and asymmetric dimethylarginine in pregnancy and fetal programming.

Authors:  Li-Tung Huang; Chih-Sung Hsieh; Kow-Aung Chang; You-Lin Tain
Journal:  Int J Mol Sci       Date:  2012-11-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.